Cygnus Completes $10 Million Asset Sale to Animas

Cygnus announced that it completed the sale of substantially all of its assets (other than cash and cash equivalents, accounts receivable and its rights in the arbitration matter with Ortho-McNeil Pharmaceutical) to Animas and Animas Technologies for $10 million in cash. The assets sold include the company's intellectual property; product development and production equipment; regulatory package; inventory; and certain assumed contracts, including all supplier, manufacturing and license agreements relating to the company's glucose monitoring technology and GlucoWatch Biographer line of products.

Yahoo News (http://biz.yahoo.com/prnews/050323/sfw076_4.html)